This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

24 Jul 2012

KDDF Chooses Parexel to Support Global Drug Development And Commercialisation

Global biopharmaceutical services provider Parexel has announced an alliance with the KDDF to accelerate global drug development.

Parexel International Corporation has announced that it has been chosen by the Korea Drug Development Fund (KDDF) to help Korean pharmaceutical companies develop and commercialise healthcare products for worldwide distribution.


The biopharmaceutical services provider will help companies to access patient populations, navigate regulatory issues and ensure a high level of data quality, thereby helping to speed up the drug development and commercialisation process.


Ron Kraus, corporate vice-president and worldwide head of Parexel Consulting and Medical Communications Services, said that the KDDF - which was established in September 2011 - will be an "important resource" for emerging biopharmaceutical companies.<

Related News